Merck leads CHF 10.5m series-A for Inthera Bioscience

Aglaia Biomedical Ventures and Novo Seeds also participated in the round alongside an unnamed private investor.

The new funds will be used to complete pre-clinical development of a targeted therapy for solid tumours. Inthera will also add to its current staff of three and expand operations.

Previous funding
MS Ventures, Aglaia Oncology Fund II and Novo Seeds led a €3.5m seed round for Inthera in December 2015. EVA Basel also contributed to the financing round.

Company
Inthera was founded in 2013 by Ulrich Kessler and Paramjit Arora. Arora developed the technology during his research at New York University and was approached by Kessler. Jasper Bos of Merck Ventures worked with the two founders from a very early stage to refine the business plan and secure the appropriate funding.

The company uses a proprietary trademarked technology to design therapies for solid tumours and currently employs three people.

People
Inthera Biosciences – Ulrich Kessler, Paramjit Arora (co-founders).
Merck Ventures – Jasper Bos (vice-president).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Switzerland
• Venture